Short answer
Tectonic Therapeutic, Inc. (TECX) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Phase 1 TX2100 results favorable for safety, tolerability and pharmacokinetics.
Tectonic Therapeutic, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Phase 1 TX2100 results favorable for safety, tolerability and pharmacokinetics
- TX2100 targets hereditary hemorrhagic telangiectasia, expanding Tectonic’s clinical pipeline
- Press release dated September 29, 2026, contains substantive trial details in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Phase 1a TX2100 doses generally safe and tolerated across six cohorts in 48 healthy volunteers
- No deaths, serious adverse events, or severe treatment-emergent adverse events; anti-drug antibody results pending
- FDA Fast Track designation and IND clearance advance TX2100 into HHT patient testing
- Phase 1b planned by year-end 2026, with placebo-controlled Phase 2 planned for early 2027
- PK supports potential once-weekly or every-other-week subcutaneous dosing; efficacy remains unproven in patients
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Tectonic Therapeutic, Inc. 8-K filings
Get the next TECX 8-K as it lands
Follow TECX for push alerts, or ask the research agent what this filing means.